[1]
Makler A, Narayanan R. Mining exosomal genes for pancreatic cancer targets. Cancer Genomics Proteomics 2017; 14: 161-72.
[2]
Narayanan R. Druggable cancer secretome: Neoplasm-associated traits. Cancer Genomics Proteomics 2015; 12: 119-32.
[3]
Delgado AP, Chapado M, Brandao P, Hamid S, Narayanan R. Atlas of the open reading Frames in human diseases: Dark matter of the human genome. MOJ Proteom Bioinform 2015; 2(1): 00036.
[4]
Narayanan R. Phenome-Genome association studies of pancreatic cancer: New targets for therapy and diagnosis. Cancer Genomics Proteomics 2015; 12: 9-20.
[5]
Delgado AP, Hamid S, Brandao P, Narayanan R. A novel transmembrane glycoprotein cancer biomarker present in the X chromosome. Cancer Genomics Proteomics 2014; 11(2): 81-92. a
[6]
Delgado AP, Brandao P, Chapado M, Hamid S, Narayanan R. Open reading frame associated with the dark matter of the human genome. Cancer Genomics Proteomics 2014; 11: 201-14. b
[7]
Delgado AP, Brandao P, Narayanan R. Mining the dark matter of the cancer proteome for novel biomarkers. Curr Cancer Ther Rev 2013; 9: 1-13.
[8]
Aleman MJ, DeYoung MP, Tress M, Keating P, Perry G. Narayanan R. Inhibition of single minded 2 gene expression mediates tumor-selective apoptosis and differentiation in human colon cancer cells. Proc Natl Acad Sci USA 2005; 102(36): 127650-70.
[9]
DeYoung MP, Scheurle D, Damania H, Zylberberg C, Narayanan R. Down’s syndrome-associated single minded gene as a novel tumor marker. Anticancer Res 2002; 22: 3149-58.
[10]
DeYoung MP, Tress M, Narayanan R. Identification of Down’s syndrome critical locus gene SIM2 as a novel drug therapy target for solid tumors Proc Natl Acad Sci USA 2003; 100: 4760-5. Also see GNN news and TIPS review 2003, 24(10): 508-10.
[11]
DeYoung MP, Tress M, Narayanan R. Down’s syndrome associated Single Minded gene 2 as a pancreatic cancer drug therapy target. Cancer Lett 2003; 200(1): 25-31.
[12]
Scheurle D, DeYoung MP, Binninger DM, Page H, Jahanzeb M, Narayanan R. Cancer gene discovery using digital differential display. Cancer Res 2000; 60: 4037-43.
[13]
Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R. Expression profile of the putative catalytic subunit of telomerase gene. Cancer Res 1998; 58: 622-5.
[14]
Ramakrishnan S, Sharma HW, Farris AD, et al. Characterization of human telomerase complex. Proc Natl Acad Sci USA 1997; 94: 10075-9.
[15]
Zhu X, Kumar R, Mandal M, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci USA 1996; 93: 6091-5.
[16]
Higgins KA, Perez JR, Coleman TA, et al. Antisense inhibition of the p65 subunit of NF-kB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 1993; 90: 9901-5.
[17]
Narayanan R, Klement JF, Ruben SM, Higgins KA, Rosen CA. Identification of a naturally occurring transforming variant of the p65 subunit of NF-kB. Science 1992; 256: 367-70.
[18]
Narayanan R, Schaapveld RQ, Cho KR, et al. Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts. Oncogene 1992; 7: 553-61.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
49
4
1